Tango Therapeutics, Inc. (TNGX) — Financial statements
Income statement, balance sheet, and cash flow for Tango Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 62↑48.3% | 42↑15.2% | 37↑46.9% | 25↓32.9% | 37 | |
| Cost of Revenue | 2 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 60↑42.9% | 42↑15.2% | 37↑46.9% | 25↓32.9% | 37 | |
| Operating Expenses | ||||||
| R&D Expenses | 132↓8.2% | 144↑24.9% | 115↑8.8% | 106↑36.4% | 78 | |
| General & Administrative Expenses | 42↓5.1% | 44↑23.2% | 36↑18.2% | 30↑70.6% | 18 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 42↓5.1% | 44↑23.2% | 36↑18.2% | 30↑70.6% | 18 | |
| Other Expenses | -2 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 171↓8.7% | 188↑24.5% | 151↑10.9% | 136↑42.7% | 95 | |
| Total Costs & Expenses | 174↓7.5% | 188↑24.5% | 151↑10.9% | 136↑42.7% | 95 | |
| Operating Results | ||||||
| Operating Income | -111↑23.6% | -146↓27.5% | -114↓2.8% | -111↓90.9% | -58 | |
| Depreciation & Amortization | 2↓8.7% | 2↑3.5% | 2↑50.2% | 2↑79.3% | 0.90 | |
| EBITDA | -109↑23.8% | -143↓28.0% | -112↓2.1% | -109↓91.1% | -57 | |
| EBIT | -111↑23.6% | -146↓27.5% | -114↓2.8% | -111↓90.9% | -58 | |
| Interest & Other Income | ||||||
| Net Interest Income | 6↓28.6% | 8↑19.2% | 7↑354.6% | 1↑194.1% | 0.50 | |
| Interest Income | 6↓28.6% | 8↑19.2% | 7↑354.6% | 1↑194.1% | 0.50 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 10↓37.4% | 16↑23.4% | 13↑326.0% | 3↑1093.9% | 0.25 | |
| Income Before Tax | -102↑21.9% | -130↓28.0% | -102↑6.0% | -108↓86.6% | -58 | |
| Income Tax Expense | 0.00↓98.1% | 0.21↑55.2% | 0.13↑148.1% | 0.05↓81.5% | 0.29 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -102↑22.0% | -130↓28.1% | -102↑5.9% | -108↓85.8% | -58 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -102↑22.0% | -130↓28.1% | -102↑5.9% | -108↓85.8% | -58 | |
| Bottom-Line Net Income | -102↑22.0% | -130↓28.1% | -102↑5.9% | -108↓85.8% | -58 | |
| EPS (Basic) | -0.87↑26.9% | -1.19↓10.2% | -1.08↑12.2% | -1.23↓30.9% | -0.94 | |
| EPS (Diluted) | -0.87↑26.9% | -1.19↓10.2% | -1.08↑12.2% | -1.23↓30.9% | -0.94 | |
| Weighted Average Shares | 116↑6.4% | 109↑15.5% | 95↑7.7% | 88↑41.4% | 62 | |
| Weighted Average Diluted Shares | 116↑6.4% | 109↑15.5% | 95↑7.7% | 88↑41.4% | 62 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.